Compare Meta Platforms Inc (META) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Sana Biotechnology Inc — how do they compare? Meta Platforms Inc trades at $579.44 (market cap $1.53T), while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: Meta Platforms Inc is far larger — about 1354× Sana Biotechnology Inc's market cap, and Meta Platforms Inc pays a 0.35% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| META | SANA | |
|---|---|---|
Market Cap | $1.53T | $1.13B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $5.92 |
52-Week Low | $525.72 | $2.68 |
Enterprise Value | $1.55T | $1.05B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META trades at $579.51, down 2.59% in 24 hours, with a neutral technical signal and bearish moving averages. The company reported strong revenue growth to $200.97B in 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of its Muse Spark AI model and a legal ruling in Massachusetts regarding youth addiction lawsuits.
The outlook remains positive with a consensus price target of $761.95 and 79% buy ratings from analysts, driven by AI innovation and solid fundamentals. Risks include regulatory challenges and high capital expenditures, but earnings beats and institutional buying support long-term growth potential.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
